Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1

Trial Profile

Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2019

At a glance

  • Drugs Rexlemestrocel-L (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms DREAM HF-1
  • Sponsors Mesoblast; Teva Pharmaceutical Industries
  • Most Recent Events

    • 02 Apr 2019 Status changed from recruiting to active, no longer recruiting.
    • 07 Jan 2019 According to a Mesoblast media release, 570 patients are recruited in this study.
    • 28 Dec 2018 According to a Mesoblast media release, the company expects to complete patients recruitment in this study very shortly.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top